QG

Qiagen NVNYSE QGEN Stock Report

Last reporting period 30 Jun, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

9.952

Middle

Exchange

XNYS - New York Stock Exchange, Inc

QGEN Stock Analysis

QG

Avoid

Based on Eyestock quantitative analysis, QGEN`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

50/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-78.5 %

Greatly overvalued

Market cap $B

9.952

Dividend yield

2.92 %

Shares outstanding

227.72 B

QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 6,178 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

View Section: Eyestock Rating